[go: up one dir, main page]

MX2019000342A - Composiciones y metodos para tratar y/o prevenir enfermedades de almacenamiento lisosomal y otras enfermedades metabolicas monogeneticas. - Google Patents

Composiciones y metodos para tratar y/o prevenir enfermedades de almacenamiento lisosomal y otras enfermedades metabolicas monogeneticas.

Info

Publication number
MX2019000342A
MX2019000342A MX2019000342A MX2019000342A MX2019000342A MX 2019000342 A MX2019000342 A MX 2019000342A MX 2019000342 A MX2019000342 A MX 2019000342A MX 2019000342 A MX2019000342 A MX 2019000342A MX 2019000342 A MX2019000342 A MX 2019000342A
Authority
MX
Mexico
Prior art keywords
compositions
treating
diseases
methods
lysosomal storage
Prior art date
Application number
MX2019000342A
Other languages
English (en)
Inventor
D Claypool William
Original Assignee
Ranedis Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranedis Pharmaceuticals Llc filed Critical Ranedis Pharmaceuticals Llc
Publication of MX2019000342A publication Critical patent/MX2019000342A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención incluye composiciones para tratar una enfermedad o trastorno de almacenamiento lisosomal y métodos que las usan; en ciertas modalidades, las composiciones de la invención comprenden un inhibidor de la histona desacetilasa (HDACi), una ciclodextrina, agua, opcionalmente un polialquileno glicol y opcionalmente dimetil sulfóxido (DMSO); en otras modalidades, las composiciones de la invención comprenden una HDACi, una ciclodextrina, agua, un polialquileno glicol y DMSO.
MX2019000342A 2016-07-08 2017-07-05 Composiciones y metodos para tratar y/o prevenir enfermedades de almacenamiento lisosomal y otras enfermedades metabolicas monogeneticas. MX2019000342A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662360012P 2016-07-08 2016-07-08
US201762513231P 2017-05-31 2017-05-31
PCT/US2017/040703 WO2018009531A1 (en) 2016-07-08 2017-07-05 Compositions and methods of treating and/or preventing lysosomal storage diseases and other monogenetic metabolic diseases

Publications (1)

Publication Number Publication Date
MX2019000342A true MX2019000342A (es) 2019-09-04

Family

ID=60913099

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019000342A MX2019000342A (es) 2016-07-08 2017-07-05 Composiciones y metodos para tratar y/o prevenir enfermedades de almacenamiento lisosomal y otras enfermedades metabolicas monogeneticas.

Country Status (9)

Country Link
US (1) US20190224146A1 (es)
EP (1) EP3481376A4 (es)
JP (1) JP2019524879A (es)
CN (1) CN109715141A (es)
AU (1) AU2017292776A1 (es)
CA (1) CA3030142A1 (es)
IL (1) IL264124A (es)
MX (1) MX2019000342A (es)
WO (1) WO2018009531A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018226939A1 (en) * 2017-06-07 2018-12-13 Ranedis Pharmaceuticals, Llc Compositions and methods of treating and/or preventing cancer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001081031A (ja) * 1999-08-30 2001-03-27 Schering Ag 溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤
CA2596867A1 (en) * 2005-02-28 2006-09-08 Kosan Biosciences Incorporated Pharmaceutical formulations containing 17-allylamino-17-demethoxygeldanamycin
BRPI0610128B1 (pt) * 2005-05-13 2021-12-07 Topotarget Uk Limited Composição farmacêutica, e, uso de uma composição
US7648976B2 (en) * 2005-11-23 2010-01-19 Bristol-Myers Squibb Company 17-allylamino-17-demethoxygeldanamycin polymorphs and formulations
ITRM20070038A1 (it) * 2007-01-26 2008-07-27 Uni Degli Studi Di Roma La Sapienza Forme solubili di complessi di inclusione di inibitori dell istone deacetilasi e ciclodestrine loro processi di preparazione e impieghi in campo farmaceutico
US20100075933A1 (en) * 2008-07-28 2010-03-25 Sunita Vijay Shelke Injectable compositions of vitamin d compounds
US20140235649A1 (en) * 2011-05-24 2014-08-21 Lixte Biotechnology, Inc. Use of phosphatase inhibitors or histone deacetylase inhibitors to treat diseases characterized by loss of protein function
US9387236B2 (en) * 2011-06-10 2016-07-12 Prothera Inc. Pharmaceutical compositions containing protease and methods for the treatment of lysosomal storage diseases
FR3014694B1 (fr) * 2013-12-13 2016-11-11 Roquette Freres Compositions a base de methyl-cyclodextrines pour le traitement et/ou la prevention de maladies par augmentation du taux de cholesterol-hdl
AU2015214358A1 (en) * 2014-02-04 2016-08-18 New York University Progranulin (PGRN) and its derivatives for diagnosis and treatment of lysosomal storage diseases
MX2016016311A (es) * 2014-06-12 2017-10-12 Univ Notre Dame Du Lac Composición y método para el tratamiento de enfermedades neurológicas y lesión cerebral.
AU2017242544B2 (en) * 2016-03-31 2022-11-24 Midatech Ltd. Cyclodextrin-panobinostat adduct
CN106963752A (zh) * 2017-04-13 2017-07-21 广州赛加生物科技有限公司 一种含有组氨酸去乙酰化酶抑制剂衍生物的抗肿瘤药物

Also Published As

Publication number Publication date
US20190224146A1 (en) 2019-07-25
EP3481376A4 (en) 2020-04-08
CN109715141A (zh) 2019-05-03
WO2018009531A1 (en) 2018-01-11
IL264124A (en) 2019-02-28
JP2019524879A (ja) 2019-09-05
CA3030142A1 (en) 2018-01-11
EP3481376A1 (en) 2019-05-15
AU2017292776A1 (en) 2019-02-21

Similar Documents

Publication Publication Date Title
DK3328843T3 (da) 1,3,4-oxadiazolsulfonamidderivat-forbindelser som histon- deacetylase-6-inhibitor, og den farmaceutske sammensætning
MX2021003230A (es) Composiciones farmaceuticas que comprenden meloxicam.
DK3331864T3 (da) 1,3,4-Oxadiazolderivat-forbindelser som histon-deacetylase-6-hæmmer, og den farmaceutiske sammensætning omfattende disse
DK3362445T3 (da) Oxadiazolaminderivatforbindelser som histondeacetylase 6-inhibitor, og den farmaceutiske sammensætning dermed
MX392026B (es) Compuestos heterocíclicos como inmunomoduladores.
MX2021012547A (es) Metodos y composiciones para exterminar celulas senescentes y para tratar enfermedades y trastornos asociados con la senectud.
DK3328844T3 (da) 1,3,4-oxadiazolsulfamidderivater som histondeacetylase-6-inhibitor og farmaceutisk sammensætning omfattende samme
MX389513B (es) Compuestos heterocíclicos como inmunomoduladores.
MX2017000307A (es) Tratamiento de leucemia con inhibidores de histona deacetilasa.
PH12018501084A1 (en) Heterocyclic compounds as immunomodulators
MX2016012262A (es) Cenicriviroc para el tratamiento de fibrosis.
DK3330259T3 (da) 1,3,4-oxadiazolamidderivativ-forbindelse som histondeacetylase-6-inhibitor og farmaceutisk sammensætning indeholdende denne
BR112015023434A2 (pt) inibidores de histona deacetilase
CL2019001760A1 (es) Composiciones que comprenden ácido acético y ácido hipoclórico y métodos para tratar una biopelícula.
TW201625535A (en) Inhibitors of histone demethylases
MX2019014772A (es) Formulaciones en gel de bisfosfocinas y usos de estas.
EP3412344A4 (en) FIRE-DELAYING COMPOSITION
DK3833682T3 (da) Selvmordsmolekyle sammensætninger og fremgangsmåder
EP3496768A4 (en) ANTIMICROBIAL COMPOSITIONS AND RELATED METHODS FOR USE
MX2019007346A (es) Inhibidores de histona deacetilasa.
MX392182B (es) Combinaciones de dosis fija y formulaciones que comprenden ácido 8-hidroxi-2,2,14,14 tetrametilpentadecanodioico (etc1002) y ezetimiba y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
BR112017028139A2 (pt) inibidores de histona desacetilase
UY38352A (es) Inhibidores de integrina alfavbeta6
DK3478310T3 (da) Sammensætninger, som er anvendelige inden for forebyggelsen og/eller behandlingen af osteoartikulær inflammation og smerte samt bruskskade
EP3246037A4 (en) Crosslinked chondroitin sulfate, composition containing same, and treatment agent for eye disease